Suppr超能文献

通过调节肠道微生物群推进心血管疾病的终身精准医学。

Advancing lifelong precision medicine for cardiovascular diseases through gut microbiota modulation.

机构信息

Department of Cardiothoracic Surgery, Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Heart Center and Shanghai Institute of Pediatric Congenital Heart Disease, Shanghai Children's Medical Center, National Children's Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, China.

出版信息

Gut Microbes. 2024 Jan-Dec;16(1):2323237. doi: 10.1080/19490976.2024.2323237. Epub 2024 Feb 27.

Abstract

The gut microbiome is known as the tenth system of the human body that plays a vital role in the intersection between health and disease. The considerable inter-individual variability in gut microbiota poses both challenges and great prospects in promoting precision medicine in cardiovascular diseases (CVDs). In this review, based on the development, evolution, and influencing factors of gut microbiota in a full life circle, we summarized the recent advances on the characteristic alteration in gut microbiota in CVDs throughout different life stages, and depicted their pathological links in mechanism, as well as the highlight achievements of targeting gut microbiota in CVDs prevention, diagnosis and treatment. Personalized strategies could be tailored according to gut microbiota characteristics in different life stages, including gut microbiota-blood metabolites combined prediction and diagnosis, dietary interventions, lifestyle improvements, probiotic or prebiotic supplements. However, to fulfill the promise of a lifelong cardiovascular health, more mechanism studies should progress from correlation to causality and decipher novel mechanisms linking specific microbes and CVDs. It is also promising to use the burgeoning artificial intelligence and machine learning to target gut microbiota for developing diagnosis system and screening for new therapeutic interventions.

摘要

肠道微生物组被称为人体的第十大系统,在健康与疾病的交叉领域中发挥着至关重要的作用。肠道微生物组在个体间存在显著的变异性,这既为心血管疾病(CVD)的精准医学带来了挑战,也带来了巨大的前景。在这篇综述中,我们基于肠道微生物组在整个生命周期中的发展、演化和影响因素,总结了不同生命阶段 CVD 中肠道微生物组特征性改变的最新进展,并阐述了其在机制中的病理联系,以及靶向肠道微生物组在 CVD 预防、诊断和治疗方面的重点成果。可以根据不同生命阶段的肠道微生物组特征制定个性化策略,包括肠道微生物组-血液代谢物联合预测和诊断、饮食干预、生活方式改善、益生菌或益生元补充。然而,要实现终生心血管健康的承诺,需要从相关性到因果关系进行更多的机制研究,以揭示特定微生物与 CVD 之间的新机制。利用新兴的人工智能和机器学习技术靶向肠道微生物组开发诊断系统和筛选新的治疗干预措施也具有广阔的前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3c4/10900281/2b9b9d1be1ae/KGMI_A_2323237_F0001_OC.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验